Try adjusting your type
14th October, 2009
European Survey on Standards of Care in paediatric oncology centres. J. R. Kowalczyk, M. Samardakiewicz, K. Pritchard-Jones, R. Ladenstein, S. Essiaf, E. Fitzgerald, G. Petrarulo, G. Vassal - EJC , Volume 61, pp 11-19
8th December, 2014
The purpose of this website is to provide good and clear information about the long-term effects of childhood cancer and to refer to the various late-effects outpatient clinics (LATER outpatient clinics) that exist in the Netherlands.
8th September, 2015
Cancer in young people is rare, but it is still a major health issue in Europe. Each year, more than 6,000 young people in Europe die of cancer. There are more than 300,000 European childhood cancer survivors (in 2020, they will be nearly half a million): two-thirds of them have some late side effects of treatment, that are severe and impact on the daily life of half of those affected.
Lobular carcinoma in situ (LCIS) is a condition that indicates the presence of abnormal cells in the lobules of the breast. Although not a cancer itself, LCIS is considered a marker for increased risk of developing breast cancer in the future. It’s often detected during a biopsy for another breast condition or during a mammogram.
Lobular Carcinoma In Situ (LCIS) is a relatively unknown topic for many individuals outside the medical community. This may be attributed, in part, to the complexity of the disease and its sporadic occurrence rate. However, given its potential ramifications on healthcare, a comprehensive understanding of LCIS becomes crucial. This article seeks to bridge this gap in knowledge.
The term “carcinoma” refers typically to a kind of cancer that starts in cells making up the skin or the tissue lining organs, such as the liver or kidneys. There are various types of carcinoma including squamous cell, adenocarcinoma, basal cell carcinoma, and ductal carcinoma in situ.
Each cancer type is unique and has its distinct characteristics. However, they share a common factor in that they begin in the cells and gradually proliferate, potentially leading to significant health problems if not diagnosed and treated promptly.
LCIS, derived from the Latin ‘in situ’ meaning ‘in its original place’, is a condition where abnormal cells are found in the lobules of the breast- the milk-producing glands. Although LCIS itself is not breast cancer, it is considered a marker of increased risk of developing invasive breast cancer in either breast in the future.
Lobular cells are present in the breast’s milk-producing glands. Occasionally, these cells may undergo abnormal changes and growth to form LCIS. Experts maintain that LCIS starts when cells in the breast lobules grow and multiply excessively, resulting in more cells than normal. These cells are abnormal but do not grow into the breast tissue, remaining ‘in situ’.
Being a non-invasive form of breast disease, LCIS indicates an increased risk of developing invasive breast cancer in both breasts.
Often women with LCIS do not show symptoms, and LCIS is usually found when a biopsy is performed for another breast concern. Your doctor may advise a biopsy if routine mammograms disclose unusual findings. The diagnosis of LCIS is confirmed via breast biopsy, either a core needle biopsy or a surgical biopsy.
The biopsy results are analyzed in a lab, where a pathologist studies the tissue to determine the presence and extent of LCIS. If LCIS is detected, additional tests may be required to rule out invasive cancer.
As LCIS is not cancer but a marker for potential future breast cancer, treatment can range from careful monitoring to more aggressive treatment strategies like hormone therapy or surgery. A patient’s overall health, personal history, and family history of breast cancer are factors to consider when developing a treatment plan.
Post-diagnosis management strategies may also vary extensively, encompassing taking medicines to lower the risk of invasive breast cancer, regular imaging tests, undertaking lifestyle changes, or having regular mammogram check-ups.
LCIS is not a common condition, but its prevalence has risen alongside the increased use of breast screening. Women who have been diagnosed with LCIS are 7-12 times more likely to develop cancer in either breast. Conversely, risk factors for LCIS are not abundantly clear due to its rarity. However, some studies have identified factors such as age, family history of breast cancer, and hormone replacement therapy as pointers towards increased risk.
In conclusion, understanding LCIS, while seemingly complex, provides pivotal information on the potential risk of developing breast cancer. Continued research and advancements in medical technology are already increasing the medical community’s understanding of diagnosing and managing LCIS effectively.
LCIS is a condition where abnormal cells are found in the lobules of the breast but do not grow into the breast tissue.
LCIS itself is not breast cancer, but an indicator of an increased risk of developing invasive breast cancer in either breast in the future.
LCIS is not an invasive cancer, and therefore survival rates are normal. However, it is an indicator of an increased risk of developing invasive breast cancer in the future. Early detection and proactive treatment significantly improve the prognosis.
Not necessarily. Treatment for LCIS varies. Some doctors may recommend regular monitoring, while others may suggest surgery, particularly if the patient has other risk factors for breast cancer.
While it’s not explicitly clear, some studies have identified factors including age, family history of breast cancer, and hormone replacement therapy as increasing the risk.
Share it
You might also like
When Randy Pausch, a computer science professor at Carnegie Mellon, was asked to give such a lecture, he didnt have to imagine it as his last, since he had recently been diagnosed with terminal cancer. But the lecture he gave, Really Achieving Your Childhood Dreams, wasnt about dying.
Surviving Triple-Negative Breast Cancer: Hope, Treatment, and Recovery
After her diagnosis of hormone-negative breast cancer, health journalist Patricia Prijatel did what any reporter would do: start investigating the disease, how it occurs, how it's treated, and how to keep it from recurring.
When Things Fall Apart: Heart Advice for Difficult Times
In the face of life's most challenging moments, when fear, anxiety, and pain threaten to overwhelm us, Pema Chödrön presents a radical yet profoundly transformative approach to living our lives.
Tuesdays with Morrie: An Old Man, a Young Man, and Life’s Greatest Lesson
Maybe it was a grandparent, or a teacher, or a colleague. Someone older, patient and wise, who understood you when you were young and searching, helped you see the world as a more profound place, gave you sound advice to help you make your way through it.
Cancer: 50 Essential Things to Do: 2013 Edition
The ground-breaking classic guide to surviving cancer—now completely updated!
The Power of Now: A Guide to Spiritual Enlightenment
n the realm of literature that offers solace and guidance in the face of profound despair, there exists an international best-seller, a timeless masterpiece whose relevance remains as potent today as it was upon its initial publication.
Option B: Facing Adversity, Building Resilience, and Finding Joy
In 2015 Sheryl Sandberg’s husband, Dave Goldberg, died suddenly at the age of forty-eight. Sandberg and her two young children were devastated, and she was certain that their lives would never have real joy or meaning again.
